A review of cardiovascular benefits of SGLT2 inhibitors

被引：3

作者：

Zhang, Yingxia ^{[1
]}

Han, Qinghua ^{[2
]}

机构：

[1] Shanxi Med Univ, Key Lab Cellular Physiol, Dept Clin Med 1, Minist Educ, Taiyuan, Shanxi, Peoples R China

[2] Shanxi Med Univ, Key Lab Cellular Physiol, Dept Cardiol, Minist Educ,Hosp 1, 85 South Jiefang Rd, Taiyuan 030001, Shanxi, Peoples R China

来源：

MEDICINE | 2022年 / 101卷 / 36期

关键词：

arrhythmia; cardiomyopathy; heart failure; hypertension; mechanism; myocardial infarction; sodium-glucose cotransporter 2 inhibitor; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; EMPAGLIFLOZIN; DAPAGLIFLOZIN; RISK; CARDIOPROTECTION; CANAGLIFLOZIN; ASSOCIATION; DISEASES; DEATH;

D O I：

10.1097/MD.0000000000030310

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Sodium-glucose cotransporter 2 inhibitor (SGLT2I) is a new type of hypoglycemic drug that targets the kidney. As research continues to advance on this topic, it has been found that SGLT2I has multiple protective effects, such as hypoglycemic, cardio-renal protective, antihypertensive, and lipid-lowering effects. This review discusses the current concepts and possible mechanisms of SGLT2I in the treatment of heart failure, myocardial infarction, hypertension, cardiomyopathy and arrhythmia to provide a reference for clinicians to use drugs more reasonably and scientifically.

引用

页数：5

共 50 条

[21] SGLT2 inhibitors for primary prevention of cardiovascular events
Raz, Itamar
Cernea, Simona
Cahn, Avivit
[J]. JOURNAL OF DIABETES, 2020, 12 (01) : 5 - 7
[22] Prescription of SGLT2 inhibitors in hospitalized cardiovascular patients
Hofer, F.
Zelniker, T. A.
Koller, L.
Kazem, N.
Schweitzer, R.
Sulzgruber, P.
Niessner, A.
[J]. WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S247 - S248
[23] Ketoacidosis and SGLT2 Inhibitors: A Narrative Review
Morace, Carmela
Lorello, Giuseppe
Bellone, Federica
Quartarone, Cristina
Ruggeri, Domenica
Giandalia, Annalisa
Mandraffino, Giuseppe
Minutoli, Letteria
Squadrito, Giovanni
Russo, Giuseppina T.
Marini, Herbert Ryan
[J]. METABOLITES, 2024, 14 (05)
[24] Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors A State-of-the-Art Review
Lopaschuk, Gary D.
Verma, Subodh
[J]. JACC-BASIC TO TRANSLATIONAL SCIENCE, 2020, 5 (06): : 632 - 644
[25] SGLT2 Inhibitors' Cardiovascular Benefits in Individuals Without Diabetes, Heart Failure, and/or Chronic Kidney Disease: A Systematic Review
Khiali, Sajad
Taban-Sadeghi, Mohammadreza
Sarbakhsh, Parvin
Khezerlouy-Aghdam, Naser
Rezagholizadeh, Afra
Asham, Hila
Entezari-Maleki, Taher
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (12): : 1307 - 1323
[26] SGLT2 INHIBITORS
Brito, M.
[J]. CLINICAL THERAPEUTICS, 2015, 37 (08) : E162 - E162
[27] Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes
Minze, Molly G.
Will, Kayley J.
Terrell, Brian T.
Black, Robin L.
Irons, Brian K.
[J]. CURRENT DIABETES REVIEWS, 2018, 14 (06) : 509 - 517
[28] SGLT2 inhibitors
Dardi, I.
Kouvatsos, T.
Jabbour, S. A.
[J]. BIOCHEMICAL PHARMACOLOGY, 2016, 101 : 27 - 39
[29] Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
不详
[J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1566): : 26 - 28
[30] SGLT2 inhibitors
Steyn, Lynda
[J]. SA PHARMACEUTICAL JOURNAL, 2018, 85 (01) : 72 - 75

← 1 2 3 4 5 →